Trial Profile

A Phase 2 Study of Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Zanubrutinib (Primary) ; Cytarabine; Etoposide; Melphalan; Semustine
Indications Mantle-cell lymphoma
Focus Therapeutic Use

Most Recent Events

12 Dec 2023 Results (n=26) assessing efficacy and safety of ZR chemo-free therapy with or without ASCT in newly diagnosed MCL patients,presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Results (n=18) assessing the efficacy and safety of ZR chemo-free therapy with or without ASCT in previously untreated MCL patients presented at the 28th Congress of the European Haematology Association
18 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com